Indonesian Pharmaceutical and Health Products Secure Potential Transactions Worth Rp34 Billion in Taiwan
Indonesian health products have attracted interest from prospective importers in Taiwan, recording potential transactions worth USD 2 million, or approximately Rp34 billion. The achievement came through participation in the Biotechnology Innovation Organization (BIO) Asia-Taiwan 2026 exhibition at the Taipei Nangang Exhibition Center in Taipei, Taiwan, from 16 to 19 July 2026. At the exhibition, Indonesian businesses opened up broader opportunities for biotechnology and health products in the Taiwanese market while expanding their networks with global industry players.
In a Ministry of Trade press release dated 24 July, the Head of the Indonesian Trade and Economic Office (KDEI) in Taipei, Arif Sulistiyo, commented on Indonesia’s participation in BIO Asia-Taiwan 2026. According to him, Indonesia’s participation is a strategic step to promote products, introduce the capacity of the national pharmaceutical industry, and strengthen Indonesia’s position in the global health industry supply chain. Indonesia also has growing opportunities to encourage research collaboration, innovation, investment, and technology transfer.
“Taiwan is one of Asia’s leading hubs for pharmaceutical and health industry development. Indonesia’s presence at BIO Asia-Taiwan 2026 opens up opportunities for market access and collaboration, as well as strengthening networks with global industry players. We are optimistic that Indonesian pharmaceutical and health products have the quality and competitiveness to become part of the global pharmaceutical and health industry supply chain,” said Arif.
The Ministry of Trade of the Republic of Indonesia, through KDEI Taipei, presented seven Indonesian companies operating in pharmaceuticals, pharmaceutical raw materials, health laboratory services, and medical devices. The companies were PT Top Rawyale Indonesia, PT Shirudo Lab Berkat Abadi, PT Kalbe Genexine Biologics, PT Indoniaga Makmur Sejahtera, PT Gebang Surya Harapan, PT Konimex, and PT Pharma Metric Lab.
Arif expressed hope that Indonesia’s successful participation in BIO Asia-Taiwan 2026 would serve as momentum to strengthen the promotion and competitiveness of national biotechnology and health products in the global market.
“Through synergy between the government and businesses, we are optimistic that Indonesia can continue to expand export market access, increase trade value, and strengthen international cooperation in the bio-industry and health sectors,” said Arif.
The exhibition participants received high appreciation from visitors, particularly for biotechnology-based raw materials, herbal extracts, pharmaceutical products, other natural health products, and health laboratory services.
Vonny Willianty, Head of Business Development & Licensing at PT Kalbe Genexine Biologics, said that participating in BIO Asia-Taiwan 2026 provided an opportunity to expand business networks. “Through BIO Asia-Taiwan, we were able to meet potential new business partners who were previously beyond our reach. This opens up greater opportunities to expand our market and explore business cooperation in Taiwan,” said Vonny.
BIO Asia-Taiwan 2026 is an event organised by the Taiwan Biotechnology Industry Organization (Taiwan BIO) together with the Biotechnology Innovation Organization (BIO). The theme this year is “Asian Inspiration, Global Impact”. The exhibition was attended by participants from more than 20 countries with around 2,200 exhibition stands. With a target of more than 10,000 business matching sessions, the exhibition is one of Asia’s most strategic platforms for promoting collaboration, investment, innovation, and commercialisation in the biotechnology and health sectors.
Source: jawawa.id (https://jawawa.id/newsitem/indonesian-pharmaceutical-and-health-products-secure-potential-transactions-worth-rp34-billion-in-taiwan-1785138615)
Originally published by bcasekuritas.co.id (https://bcasekuritas.co.id/latest-news/news/kemendag-produk-farmasi-dan-kesehatan-ri-raih-potensi-transaksi-rp34-miliar-di-taiwan), translated from Indonesian